OBJECTIVE: To develop a grading scale to predict the risk of intracerebral hemorrhage (ICH) and prognosis after treatment with IV tissue-plasminogen activator (t-PA) in patients with ischemic stroke. METHODS: We constructed a five-point scale based on NIH Stroke Scale score, extent of hypodensity on CT scan, serum glucose at baseline, and history of diabetes to predict the risk of hemorrhage after thrombolysis (HAT score). We evaluated the predictive ability of this scale, using c-statistics, in two independent cohorts: the t-PA treated group in the National Institute of Neurological Disorders and Stroke study, and consecutive patients treated with IV t-PA at our institution. RESULTS: The percentage of patients who developed any ICH after t-PA increased with higher scores in both cohorts. Collectively, the rate of any symptomatic ICH was 2% (0 point), 5% (1 point), 10% (2 points), 15% (3 points), and 44% (>3 points). The c-statistic was 0.72 (95% CI 0.65-0.79; p < 0.001) for all hemorrhages; 0.74 (0.63-0.84; p < 0.001) for symptomatic hemorrhages; and 0.79 (0.70-0.88; p < 0.001) for hemorrhages with final fatal outcome. Similar results were obtained when each cohort was analyzed separately. The score also reasonably predicted good (mRS < or = 2) (c-statistic 0.75; 0.69-0.80; p < 0.001) and catastrophic (mRS > or = 5) (0.78; 0.72-0.84; p < 0.001) functional outcomes on day 90 in the National Institute of Neurological Disorders and Stroke t-PA-treated patients. CONCLUSIONS: The hemorrhage after thrombolysis (HAT) score is a practical, quick, and easy-to-perform scale that allows reasonable risk stratification of intracerebral hemorrhage after IV tissue-plasminogen activator (t-PA). However, the prognostic value of this scale and its use to predict the net benefit from t-PA needs to be refined and prospectively confirmed in a larger cohort of patients before it can be used in clinical decision-making.
OBJECTIVE: To develop a grading scale to predict the risk of intracerebral hemorrhage (ICH) and prognosis after treatment with IV tissue-plasminogen activator (t-PA) in patients with ischemic stroke. METHODS: We constructed a five-point scale based on NIH Stroke Scale score, extent of hypodensity on CT scan, serum glucose at baseline, and history of diabetes to predict the risk of hemorrhage after thrombolysis (HAT score). We evaluated the predictive ability of this scale, using c-statistics, in two independent cohorts: the t-PA treated group in the National Institute of Neurological Disorders and Stroke study, and consecutive patients treated with IV t-PA at our institution. RESULTS: The percentage of patients who developed any ICH after t-PA increased with higher scores in both cohorts. Collectively, the rate of any symptomatic ICH was 2% (0 point), 5% (1 point), 10% (2 points), 15% (3 points), and 44% (>3 points). The c-statistic was 0.72 (95% CI 0.65-0.79; p < 0.001) for all hemorrhages; 0.74 (0.63-0.84; p < 0.001) for symptomatic hemorrhages; and 0.79 (0.70-0.88; p < 0.001) for hemorrhages with final fatal outcome. Similar results were obtained when each cohort was analyzed separately. The score also reasonably predicted good (mRS < or = 2) (c-statistic 0.75; 0.69-0.80; p < 0.001) and catastrophic (mRS > or = 5) (0.78; 0.72-0.84; p < 0.001) functional outcomes on day 90 in the National Institute of Neurological Disorders and Stroket-PA-treated patients. CONCLUSIONS: The hemorrhage after thrombolysis (HAT) score is a practical, quick, and easy-to-perform scale that allows reasonable risk stratification of intracerebral hemorrhage after IV tissue-plasminogen activator (t-PA). However, the prognostic value of this scale and its use to predict the net benefit from t-PA needs to be refined and prospectively confirmed in a larger cohort of patients before it can be used in clinical decision-making.
Authors: S C Patel; S R Levine; B C Tilley; J C Grotta; M Lu; M Frankel; E C Haley; T G Brott; J P Broderick; S Horowitz; P D Lyden; C A Lewandowski; J R Marler; K M Welch Journal: JAMA Date: 2001-12-12 Impact factor: 56.272
Authors: David Tanne; Scott E Kasner; Andrew M Demchuk; Nira Koren-Morag; Sandra Hanson; Martin Grond; Steven R Levine Journal: Circulation Date: 2002-04-09 Impact factor: 29.690
Authors: Chelsea S Kidwell; Jeffrey L Saver; Joaquin Carneado; James Sayre; Sidney Starkman; Gary Duckwiler; Y Pierre Gobin; Reza Jahan; Paul Vespa; J Pablo Villablanca; David S Liebeskind; Fernando Vinuela Journal: Stroke Date: 2002-03 Impact factor: 7.914
Authors: Marc Ribo; Joan Montaner; Carlos A Molina; Juan F Arenillas; Esteban Santamarina; Manuel Quintana; José Alvarez-Sabín Journal: Stroke Date: 2004-07-08 Impact factor: 7.914
Authors: Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton Journal: Lancet Date: 2004-03-06 Impact factor: 79.321
Authors: W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne Journal: JAMA Date: 1995-10-04 Impact factor: 56.272
Authors: Magdy Selim; John N Fink; Sandeep Kumar; Louis R Caplan; Clare Horkan; Yi Chen; Italo Linfante; Gottfried Schlaug Journal: Stroke Date: 2002-08 Impact factor: 7.914
Authors: Alexander D Horsch; Edwin Bennink; Tom van Seeters; L Jaap Kappelle; Yolanda van der Graaf; Willem P T M Mali; Hugo W A M de Jong; Birgitta K Velthuis; Jan Willem Dankbaar Journal: Cerebrovasc Dis Date: 2018-01-08 Impact factor: 2.762
Authors: David Asuzu; Karin Nyström; Joseph Schindler; Charles Wira; David Greer; Janet Halliday; Kevin N Sheth Journal: Neurocrit Care Date: 2015-10 Impact factor: 3.210
Authors: Andrew D Barreto; Gary A Ford; Loren Shen; Claudia Pedroza; Jon Tyson; Chunyan Cai; Mohammad H Rahbar; James C Grotta Journal: Stroke Date: 2017-05-15 Impact factor: 7.914
Authors: Joshua A Stone; Joshua Z Willey; Salah Keyrouz; James Butera; Ryan A McTaggart; Shawna Cutting; Brian Silver; Bradford Thompson; Karen L Furie; Shadi Yaghi Journal: Curr Treat Options Neurol Date: 2017-01 Impact factor: 3.598
Authors: Bruce C V Campbell; Søren Christensen; Mark W Parsons; Leonid Churilov; Patricia M Desmond; P Alan Barber; Kenneth S Butcher; Christopher R Levi; Deidre A De Silva; Maarten G Lansberg; Michael Mlynash; Jean-Marc Olivot; Matus Straka; Roland Bammer; Gregory W Albers; Geoffrey A Donnan; Stephen M Davis Journal: Ann Neurol Date: 2013-02-26 Impact factor: 10.422